Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
2 days ago
Patients with chronic kidney disease appear to be at greater risk of developing type 2 diabetes mellitus (T2DM) compared with the general population, with predictors including poor baseline glycaemic control and family history of diabetes mellitus, a study has found.

Statins protect against hepatocellular carcinoma

10 Mar 2018
Statin, a blood cholesterol-lowering medicine, reduces sharply in blood cholesterol levels among ACS patients.

High-risk patients may benefit from a protective effect of statins against hepatocellular carcinoma (HCC), a recent study suggests. This effect appears to be greater in patients with diabetes mellitus (DM) or liver cirrhosis (LC).

Researchers drew data from the 2002–2013 National Health Insurance Service Physical Health Examination Cohort in the Republic of Korea. Multivariable conditional logistic regression analysis was performed to determine the association of HCC with statin use.

The use of statins was significantly less common in 1,642 HCC patients than in 8,210 age-, sex- and index date-matched controls, including simvastatin (odds ratio [OR], 0.44; 95 percent CI, 0.33–0.58), atorvastatin (OR, 0.49; 0.37–0.65), lovastatin (OR, 0.34; 0.16–0.73), rosuvastatin (OR, 0.56; 0.31–0.98) and pitavastatin (OR, 0.31; 0.13–0.77).

There was a significant association between statin use and a lower risk of HCC incidence relative to nonuse (adjusted OR, 0.44; 0.33–0.58).

Cumulative doses of statin also appeared to yield a trend of risk reduction. The corresponding adjusted ORs for <180, 180–365, 365–720 and 720 cumulative defined daily doses of statin use were 0.45 (0.32–0.64), 0.56 (0.31–1.00), 0.41 (0.22–0.76) and 0.30 (0.14–0.63).

The inhibitory effect of statins on HCC was stronger in patients with DM (adjusted OR, 0.28; 0.17–0.46) and LC (adjusted OR, 0.39; 0.26–0.70) relative to statin users without the said conditions (adjusted OR for DM, 0.53; 0.39–0.73; adjusted OR for LC, 0.42; 0.32–0.57).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
2 days ago
Patients with chronic kidney disease appear to be at greater risk of developing type 2 diabetes mellitus (T2DM) compared with the general population, with predictors including poor baseline glycaemic control and family history of diabetes mellitus, a study has found.